AstraZeneca has paid $875 million to take control of Alimirall’s respiratory drug portfolio that includes treatments for bronchitis and emphysema. …
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia

